Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Iloperidone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vanda gets $466M takeout bid from Cycle Pharma
    Vanda gets $466M takeout bid from Cycle Pharma

    06 Jun 2024

    // Eric Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/vanda-after-rejecting-future-pak-offer-gets-466m-takeout-bid-cycle-pharma

    Eric Sagonowsky FIERCE PHARMA
    06 Jun 2024
    Share Share
    Future Pak Increases Vanda Bid With CVRs, $7.25-$7.75 Per Share
    Future Pak Increases Vanda Bid With CVRs, $7.25-$7.75 Per Share

    07 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240507321726/en

    BUSINESSWIRE
    07 May 2024
    Share Share
    Vanda Fanapt Receives FDA Approval for the Acute Treatment of Bipolar I Disorder
    Vanda Fanapt Receives FDA Approval for the Acute Treatment of Bipolar I Disorder

    02 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-fanapt-iloperidone-receives-us-fda-approval-for-the-acute-treatment-of-bipolar-i-disorder-302106405.html

    PR NEWSWIRE
    02 Apr 2024
    Share Share
    Vanda Pharma announces the publication of Efficacy and Safety of Iloperidone
    Vanda Pharma announces the publication of Efficacy and Safety of Iloperidone

    17 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-iloperidone-in-bipolar-mania-a-double-blind-placebo-controlled-study-in-the-journal-of-clinical-psychiatry-302037494.html

    PR NEWSWIRE
    17 Jan 2024
    Share Share
    Fanapt Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study
    Fanapt Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

    19 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/fanapt-shown-to-be-effective-in-bipolar-i-disorder-in-phase-iii-clinical-study-301705863.html

    PRNEWSWIRE
    19 Dec 2022
    Share Share
    Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®
    Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®

    13 Jan 2020

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-wins-key-us-supreme-court-patent-ruling-on-fanapt-300985926.html

    PR NEWSWIRE
    13 Jan 2020
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.